Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Hypertension is a common condition that can cause serious events such as stroke, coronary
heart disease and heart failure. Homocysteine (Hcy) is a substance in the body that is
harmful to blood vessels. Hyperhomocysteinemia (plasma Hcy≥10 mol/L), which is associated
with hypertension, significantly increases the risk of stroke. This type of high blood
pressure is called type "H" hypertension. Enalapril folic acid tablet is an innovative drug
developed independently in China and is the first choice for the treatment of H type
hypertension. Patients with type H hypertension should be treated with enalapril folic acid
tablets to reduce stroke.
However, some patients had poor blood pressure control after monotherapy. At this time, other
antihypertensive drugs should be used in combination. Amlodipine and Hydrochlorothiazide are
the most commonly used and the best combination.
The purpose of this study was to observe the difference in the efficacy of enalapril folic
acid tablets in patients with uncontrolled blood pressure who were well tolerated and
randomized to aminoclodipine or hydrochlorothiazide in reducing stroke and other
cardiovascular and cerebrovascular events, and to explore the relationship between various
alternative measures and efficacy.
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
National Clinical Research Center, Southern Medical University Ningbo Yinzhou Community Health Service Center
Treatments:
Amlodipine Enalapril Enalaprilat Folic Acid Hydrochlorothiazide Vitamin B Complex